Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding Revolutionaries in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting directly to the Senior Director, Provider Accounts, the National Account Director, Academic/IDN Oncology (NAD) is responsible for establishing and maintaining strategic relationships to secure optimal market access for our innovative oncology medicines within Large Health Systems, Integrated Delivery Networks (IDNs), KOL stakeholders and institution specific clinical pathways. The NAD will develop and execute account plans and strategies that drive rapid pathway and protocol inclusions to support rapid access while representing the company's interests with key decision-makers. The NAD will help to coordinate cross-functional workstreams to ensure products are included when appropriate in institution-driven clinical pathways. This is a field-based remote position.